These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 35714302)
1. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. Mittendorf EA; Burgers F; Haanen J; Cascone T Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35714302 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer. Broderick SR Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists. Kifjak D; Hochmair MJ; Krenbek D; Milos RI; Heidinger BH; Prayer F; Röhrich S; Watzenboeck ML; Oberndorfer F; Klikovits T; Aigner C; Sinn K; Hoda MA; Hoetzenecker K; Haug AR; Prosch H; Beer L Eur J Radiol; 2023 Apr; 161():110732. PubMed ID: 36804313 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909 [TBL] [Abstract][Full Text] [Related]
5. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature. Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792 [TBL] [Abstract][Full Text] [Related]
6. [Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer]. Yao S; Zhang Y Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):55-59. PubMed ID: 31948539 [TBL] [Abstract][Full Text] [Related]
7. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer]. Chen XY; Yang F Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time? Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418 [TBL] [Abstract][Full Text] [Related]
10. Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non-small-cell lung cancer: a case report. Liu Y; Gao Z; Zhang C; Liu X; Liu Z; Lin X; Qian B; Jin F; Shao G; Yang Z Anticancer Drugs; 2022 Jan; 33(1):e784-e788. PubMed ID: 34419961 [TBL] [Abstract][Full Text] [Related]
11. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. Gentzler RD; Riley DO; Martin LW Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520 [TBL] [Abstract][Full Text] [Related]
13. Revisiting neoadjuvant therapy in non-small-cell lung cancer. Saw SPL; Ong BH; Chua KLM; Takano A; Tan DSW Lancet Oncol; 2021 Nov; 22(11):e501-e516. PubMed ID: 34735819 [TBL] [Abstract][Full Text] [Related]
14. A Pathologic Complete Response to Neoadjuvant Chemotherapy and Immunotherapy Followed by Surgery in a Patient With NSCLC. Ma X; Li B; Li Y; Lu L; Chen H J Thorac Oncol; 2019 May; 14(5):e104-e106. PubMed ID: 31027744 [No Abstract] [Full Text] [Related]
16. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. Burton EM; Amaria RN; Cascone T; Chalabi M; Gross ND; Mittendorf EA; Scolyer RA; Sharma P; Ascierto PA J Transl Med; 2022 Jun; 20(1):271. PubMed ID: 35706041 [TBL] [Abstract][Full Text] [Related]
17. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. Tong BC; Gu L; Wang X; Wigle DA; Phillips JD; Harpole DH; Klapper JA; Sporn T; Ready NE; D'Amico TA J Thorac Cardiovasc Surg; 2022 Feb; 163(2):427-436. PubMed ID: 33985811 [TBL] [Abstract][Full Text] [Related]
18. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer]. Wang S; Mao Y Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581 [TBL] [Abstract][Full Text] [Related]
19. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Kang J; Zhang C; Zhong WZ Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]